Home/Shionogi/Margaret Borys
MB

Margaret Borys

Executive Vice President and Chief Commercial Officer

Shionogi

Shionogi Pipeline

DrugIndicationPhase
Investigational Oral COVID-19 AntiviralCOVID-19Clinical
Fragile X ProgramFragile X SyndromeClinical
Acute Stroke ProgramAcute Ischemic StrokeClinical
Metabolic Disorders ProgramMetabolic ConditionsClinical
Oncology ProgramCancerClinical
Novel AntibioticsBacterial InfectionsVarious
HIV TherapeuticsHIV/AIDSApproved
Influenza TreatmentsInfluenzaApproved